Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02081378	Phase I	Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib	A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL	Completed	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| AUS	3
NCT02629692	Phase Ib/II	K0706	Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to >=3 Prior CML Therapies	Active, not recruiting	USA \| TUR \| ROU \| ITA \| HUN \| GBR \| FRA \| ESP \| BEL	2
NCT04793399	Phase Ib/II	Atezolizumab + Bosutinib	Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients	Terminated	ESP	0
NCT01593254	Phase II	Imatinib Dasatinib	Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)	Completed	USA \| POL \| ITA \| HUN \| FRA \| ESP \| CZE \| CAN \| BRA \| BEL \| AUT \| ARG	3
NCT02228382	FDA approved	Bosutinib	Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors	Terminated	USA \| SWE \| NOR \| ITA \| FRA \| ESP \| DEU \| AUT	0
NCT04838041	Phase II	Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib Asciminib	Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation	Recruiting	USA	0
NCT06629584	Phase II	Asciminib	Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia	Recruiting	USA	0
NCT03874858	Phase II	Nilotinib Asciminib + Nilotinib	A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia (DANTE)	Active, not recruiting	ITA	0
NCT04925479	Phase Ib/II	Asciminib	Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GRC \| FRA \| DEU	5
NCT02311998	Phase Ib/II	Bosutinib + Inotuzumab ozogamicin	Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML	Completed	USA	0
NCT04835584	Phase Ib/II	Dasatinib + KRT-232 KRT-232 + Nilotinib	KRT-232 and TKI Study in Chronic Myeloid Leukemia	Recruiting	USA \| POL \| ITA \| FRA \| ESP \| CAN	2
NCT04329325	Phase II	Dasatinib + Dexamethasone + Methotrexate Blinatumomab + Dasatinib + Methotrexate	Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Active, not recruiting	USA	0
NCT06423911	Phase III	Bosutinib + Olverembatinib Olverembatinib	Study of Olverembatinib (HQP1351) in Patients With CP-CML (POLARIS-2)	Recruiting	USA	0
NCT04160546	Phase II	Aspirin + Ponatinib	Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP) (ResToP)	Active, not recruiting	ESP	0
NCT06236724	Phase II	Asciminib	Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.	Recruiting	USA	0
NCT02782403	Phase Ib/II	Axitinib + Bosutinib	Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia	Terminated	USA	0
NCT03106779	Phase III	Bosutinib Asciminib	Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs	Completed	USA \| TUR \| ROU \| NLD \| LBN \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| AUS \| ARG	6
NCT05384587	Phase II	Asciminib	Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE)	Active, not recruiting	USA	0
NCT01744665	Phase II	Nilotinib	Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5. (ENESTgoal)	Completed	USA	0
NCT01746836	Phase II	Ponatinib	Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib	Recruiting	USA	0
NCT02538926	Phase II	Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Sulfate Asparaginase	Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Withdrawn	USA	0
NCT03595917	Phase I	Asciminib + Blinatumomab + Dasatinib + Prednisone	ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML	Recruiting	USA	0
NCT03459534	Phase III	Radotinib	A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs	Recruiting	TUR	3
NCT06163430	Phase I	TERN-701	CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia	Recruiting	USA \| ITA \| FRA \| ESP \| DEU \| AUS	1

Profile Name	ABL1 T315I
Gene Variant Detail	ABL1 T315I (unknown)
Relevant Treatment Approaches

Molecular Profile Detail

Contact

Filtering

Sorting